Supernus (SUPN) Earnings Date & Reports

Key Takeaways

• Supernus reported record third-quarter 2026 total revenue of $226.8 million, up 18% year over year and above consensus estimates of roughly $218 million.
• GAAP (Generally Accepted Accounting Principles) net income reached $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or a loss of $0.80 per share, in the prior-year quarter.
• Adjusted (non-GAAP) operating earnings rose to $55.2 million from $41.9 million a year earlier.
• Combined revenue from the four growth products — Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO — climbed 43% year over year.
• Management raised full-year 2026 revenue guidance to $875 million–$900 million and adjusted operating earnings guidance to $160 million–$180 million.
• The all-stock merger with Indivior Pharmaceuticals was approved by both companies' shareholders and is expected to close on November 2, 2026.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover Trending AI Robots for AI-driven market signals and trade ideas.

Earnings Context and Why It Matters

This quarterly earnings release arrives at a pivotal moment for Supernus Pharmaceuticals, a Rockville, Maryland-based biopharmaceutical company focused on central nervous system (CNS) diseases. The report lands just days before the company's planned all-stock combination with Indivior Pharmaceuticals, a merger that would create a diversified CNS leader spanning psychiatry, neurology, and addiction. Investors are watching whether Supernus can sustain the momentum of its growth portfolio — particularly Qelbree, ZURZUVAE, GOCOVRI, and ONAPGO — while demonstrating improved operating efficiency. The results also matter because they reflect the final standalone quarter before the combined entity begins trading, offering a baseline for assessing the merger's integration and cost-synergy story.

Reported Results

Supernus delivered record total revenue of $226.8 million for the third quarter ended September 30, 2026, an 18% increase from $192.1 million in the same period last year. The figure topped Wall Street consensus estimates, which clustered near $218 million. Net product sales totaled $178.6 million, while collaboration revenue tied to ZURZUVAE reached $41.7 million and royalty, licensing, and other revenue contributed $6.5 million.

On the bottom line, GAAP net earnings were $20.9 million, or $0.35 per diluted share, a sharp turnaround from a GAAP net loss of $45.1 million, or a loss of $0.80 per diluted share, a year earlier. GAAP operating earnings came in at $21.2 million versus an operating loss of $60.2 million in the prior-year quarter. Adjusted (non-GAAP) operating earnings rose to $55.2 million from $41.9 million, reflecting the absence of acquisition-related costs tied to the 2025 Sage Therapeutics transaction.

Growth-product momentum was a clear highlight. Qelbree generated $90.8 million in net sales, GOCOVRI reached a record $42.6 million, ONAPGO grew to $17.1 million, and ZURZUVAE collaboration revenue more than doubled. Management also raised standalone 2026 guidance, lifting total revenue to $875 million–$900 million and adjusted operating earnings to $160 million–$180 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market more efficiently. The screener scans thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By applying AI-driven signals alongside fundamental and trend-based filters, it can surface trade ideas, trending names, and breakout candidates far faster than manual screening. For investors following SUPN and its peers across the pharmaceutical sector, the AI Screener offers a practical way to identify opportunities and monitor market conditions in one place.

Market Reaction and Investor Sentiment

Despite revenue and earnings that beat the prior year and exceeded revenue consensus, the stock's immediate reaction was muted. Shares slipped roughly 2% in early post-report trading, suggesting that some investors had already priced in the strong growth-product trajectory and were looking ahead to the merger close. The conflicting analyst EPS expectations also muddy the picture: some consensus figures anticipated a small loss, while others modeled a higher profit, making the headline EPS comparison less straightforward.

Investor sentiment remains focused less on the standalone quarter and more on execution of the Indivior combination. With shareholder approval secured on October 15 and a November 2 closing expected, attention is shifting to integration risk, the realization of the $125 million in anticipated annual cost synergies, and how the combined 11-product portfolio performs in 2027.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important catalyst is the closing of the Indivior merger on November 2, 2026. Once complete, the standalone guidance issued this quarter will no longer apply, and the market will focus on the combined company's revised financial framework and integration timeline. Management expects to provide combined full-year guidance shortly after closing.

Investors should watch whether the growth portfolio sustains its momentum into 2027. Qelbree's prescriptions grew 18% year over year in the quarter, outpacing the broader ADHD (attention-deficit hyperactivity disorder) market, while ZURZUVAE's U.S. sales, as reported by Biogen, rose approximately 53%. ONAPGO also gained a favorable regulatory tailwind after the FDA (U.S. Food and Drug Administration) recognized seven years of orphan drug exclusivity.

Additional factors to monitor include progress on pipeline programs such as SPN-820 and SPN-817, which continue enrolling in Phase IIb studies, and the SPN-443 program, expected to begin a Phase I study by the end of 2026. Cost discipline, margin trends, and the pace of merger cost-synergy capture will also shape how investors assess the newly combined entity in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations